Sisram Medical Announces 2022 Annual Results.

HONG KONG: Sisram Medical Ltd (the "Company" or "Sisram",: 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group, featuring a first-of-its-kind synergistic ecosystem of business building blocks and consumer-focused branding, ranging from Energy Based Devices, injectables, aesthetics and digital dentistry, personal care and more, today announced its audited consolidated annual results for the year ended December 31, 2022 (the "Reporting Period").

2022 ANNUAL FINANCIAL HIGHLIGHTS

Revenue was US$354.5 million, representing an increase of 20.5% YoY.

Profit was US$40.1 million, an increase of 23.2% YoY.

Gross profit margin increased to 57.0% from 56.7% for the corresponding period in 2021. The increase is mainly driven by the continued expansion of the direct sales portion.

The Company saw significant growth in all regions, mainly in North America, APAC, and the Middle East. Revenues in North America were US$143.7 million, an increase of 28.2% YoY. Revenues generated from APAC were US$98.1 million, an increase of 15.1% YoY. Revenues in the Middle East and Africa were US$36.6 million, an increase of 18.7% YoY.

KEY ACHIEVEMENTS

The company maintained consistent investment in R&D, introduced three brand new products, and successfully promoted two existing products to new markets.

New products introduced: 1) Alma Ted, an ultrasound-based system to meet the market's growing hair loss needs; 2) CBD+ Professional Skincare Solution, a professional skincare solution to visibly reduce redness and calm the appearance of stressed skin; 3) LMNT one, the B2C product designed with a light-based skin rejuvenation treatment to achieve skin rejuvenation through multiple dimensions such as giving an instant glow and promoting collagen production in the comfort of consumers' homes.

Existing products promoted to new markets: 1) Alma Hybrid creates a unique synergistic effect by combining the power of three core energies and enabling endless options for ablative, non-ablative and thermal treatments for skin rejuvenation and scar revision. The system was launched in Europe in 2020 and in the U.S. in 2021, and then was introduced in Canada in August 2022; 2) Alma Duo, an advanced, effective, and FDA cleared solution to promote blood flow to the sexual organs to restore natural function, was successfully launched in the global market in November 2022.

Diversified product portfolio to enrich injectable and...